Patient values and preferences in decision making for antithrombotic therapy: A systematic review - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

Chest

Volumn 141, Issue 2 SUPPL., 2012, Pages e1S-e23S

  MacLean, Samantha ^a   Mulla, Sohail ^a   Akl, Elie A ^a,d   Jankowski, Milosz ^b   Vandvik, Per Olav ^e   Ebrahim, Shanil ^a   McLeod, Shelley ^c   Bhatnagar, Neera ^a   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c WESTERN UNIVERSITY   (Canada)

^d UNIVERSITY AT BUFFALO   (United States)

^e INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG UTILIZATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION PREVENTION; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; LIFESTYLE; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PATIENT SATISFACTION; PATIENT VALUES; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84856785571     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2290     Document Type: Article

References (57)

1. Oxman AD, Schünemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:28.
2. Montori V, Devereaux P, Straus S, et al. Advanced topics in moving from evidence to action: decision making and the patient. Chapter 22.2. In: Guyatt G, Drummond R, Meade MO, Cook D, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York, NY:American Medical Association; 2008.
3. Alonso-Coello P, Montori VM, Solà I, et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res. 2008;8:21.
4. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001; 323(7323):1218-1222.
5. Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation-semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608-611. (Pubitemid 39504295)
6. Gage BF, Cardinalli AB, Albers GW, Owens DK. Costeffectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274(23):1839-1845. (Pubitemid 26001259)
7. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156(16):1829-1836. (Pubitemid 26295228)
8. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29(6):1083-1091. (Pubitemid 28265459)
9. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ. 1999;318(7194):1324-1327. (Pubitemid 29219046)
10. Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ. Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. CMAJ. 2007;176(11):1583-1587. (Pubitemid 46868606)
11. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e152S-e184S.
12. Man-Son-Hing M. The Efficacy of Warfarin for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: Measuring Its Minimal Clinically Important Difference From the Patients' Perspective [master's thesis]. Ottawa, Ontario, Canada: University of Ottawa; 1996 :148-148.
13. Man-Son-Hing M, Laupacis A, O'Connor AM, et al Stroke Prevention in Atrial Fibrillation Investigators. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA. 1999;282(8):737-743. (Pubitemid 29404379)
14. Man-Son-Hing M, O'Connor AM, Drake E, Biggs J, Hum V, Laupacis A. The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial. Health Expect. 2002;5(3):246-255. (Pubitemid 34988190)
15. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320(7246):1380-1384. (Pubitemid 30261119)
16. Sudlow M, Thomson R, Kenny RA, Rodgers H. A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. Br J Gen Pract. 1998;48(436):1775-1778. (Pubitemid 28508442)
17. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355(9208):956-962. (Pubitemid 30148260)
18. Thomson RG, Eccles MP, Steen IN, et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care. 2007;16(3):216-223. (Pubitemid 46972867)
19. Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. Am J Cardiovasc Drugs. 2009;9(1):45-58.
20. Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost. 2004;92(6):1336-1341. (Pubitemid 39642545)
21. Locadia M, Stalmeier PF, Oort FJ, Prins MH, Sprangers MA, Bossuyt PM. A comparison of 3 valuation methods for temporary health states in patients treated with oral anticoagulants. Med Decis Making. 2004;24(6):625-633. (Pubitemid 39525181)
22. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4(1): 49-56. (Pubitemid 127434425)
23. O'Meara JJ III, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med. 1994;330(26):1864-1869. (Pubitemid 24188139)
24. Bergus GR, Levin IP, Elstein AS. Presenting risks and benefits to patients. J Gen Intern Med. 2002;17(8):612-617.
25. Man-Son-Hing M, Laupacis A, O'Connor AM, Coyle D, Berquist R, McAlister F. Patient preference-based treatment thresholds and recommendations: a comparison of decisionanalytic modeling with the probability-tradeoff technique. Med Decis Making. 2000;20(4):394-403.
26. Man-Son-Hing M, Hart RG, Berquist R, O'Connor AM, Laupacis A. Differences in treatment preferences between persons who enroll and do not enroll in a clinical trial. Ann R Coll Physicians Surg Can. 2001; 34(5):292-296.
27. Montori VM, Bryant SC, O'Connor AM, Jorgensen NW, Walsh EE, Smith SA. Decisional attributes of patients with diabetes: the aspirin choice. Diabetes Care. 2003;26(10): 2804-2809. (Pubitemid 37205550)
28. Kapral MK, Devon J, Winter AL, Wang J, Peters A, Bondy SJ. Gender differences in stroke care decision-making. Med Care. 2006;44(1):70-80. (Pubitemid 43755482)
29. Mangset M, Berge E, Førde R, Nessa J, Wyller TB. "Two percent isn't a lot, but when it comes to death it seems quite a lot anyway": patients' perception of risk and willingness to accept risks associated with thrombolytic drug treatment for acute stroke. J Med Ethics. 2009;35(1):42-46.
30. Slot KB, Berge E. Thrombolytic treatment for stroke: patient preferences for treatment, information, and involvement. J Stroke Cerebrovasc Dis. 2009;18(1):17-22.
31. Heyland DK, Gafni A, Levine MA. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective. J Clin Epidemiol. 2000;53(9): 888-894.
32. Stanek EJ, Cheng JW, Peeples PJ, Simko RJ, Spinler SA. Patient preferences for thrombolytic therapy in acute myocardial infarction. Med Decis Making. 1997;17(4):464-471. (Pubitemid 27444318)
33. Tsui W, Pierre K, Massel D. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefi ts versus costs, high technology versus drugs. Can J Cardiol. 2005;21(5):423-431. (Pubitemid 40740443)
34. Anand S, Asumu T. Patient acceptance of a foot pump device used for thromboprophylaxis. Acta Orthop Belg. 2007;73(3):386-389.
35. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: A case-control study. Am J Med. 1997;103(1):11-17. (Pubitemid 27314182)
36. Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient's point of view. Thromb Haemost. 2000;83(1):49-53. (Pubitemid 30045476)
37. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632-636. (Pubitemid 40396615)
38. Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA. Patients' perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin. 2005; 21(7):1085-1090. (Pubitemid 41032699)
39. Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5:15.
40. Jaffary F, Khan T, Kamali F, Hutchinson M, Wynne HA. The effect of stability of oral anticoagulant therapy upon patientperceived health status and quality of life. J Am Geriatr Soc. 2003;51(6):885-887. (Pubitemid 36693447)
41. Lancaster TR, Singer DE, Sheehan MA, et al Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Arch Intern Med. 1991; 151(10):1944-1949.
42. Locadia M, Sprangers MA, de Haes HC, Büller HR, Prins MH. Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis. Thromb Haemost. 2003;90(1):101-107. (Pubitemid 36873865)
43. Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005;19(3):197-201. (Pubitemid 40668078)
44. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ. 2006;332(7541):577-580. (Pubitemid 44365756)
45. Maxwell GL, Synan I, Hayes RP, Clarke-Pearson DL. Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients. Obstet Gynecol. 2002;100(3):451-455. (Pubitemid 35246130)
46. Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004;2:22.
47. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deepvein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am. 1998;80(8):1158-1166. (Pubitemid 28415438)
48. Le Sage S, McGee M, Emed JD. Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients. J Vasc Nurs. 2008;26(4):109-117.
49. Prins MH, Guillemin I, Gilet H, et al. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009;7:30.
50. Koopman MMW, Prandoni P, Piovella F, et al The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334(11):682-687.
51. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279(16):1273-1277.
52. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med. 1996;156(16):1841- 1848. (Pubitemid 26295230)
53. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA. 1999;282(8):737-743. (Pubitemid 29404379)
54. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002;162(5): 541-550. (Pubitemid 34193541)
55. Tversky A, Kahneman D. Loss aversion in riskless choice: a reference-dependent model. Q J Econ. 1991; 106(4):1039-1061.
56. Draycott S, Dabbs A. Cognitive dissonance. 1: An overview of the literature and its integration into theory and practice in clinical psychology. Br J Clin Psychol. 1998;37(Pt 3): 341-353. (Pubitemid 28454301)
57. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic review. J R Soc Med. 2003;96(3):118-121. (Pubitemid 36359598)